TMDX TransMedics Group Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TMDX

Price (delayed)

$71.36

Market cap

$2.47B

P/E Ratio

14.13

Dividend/share

N/A

EPS

$5.05

Enterprise value

$2.85B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 92

TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need ...

Highlights
TMDX's equity has surged by 86% year-on-year and by 4.4% since the previous quarter
TMDX's P/E is 62% below its last 4 quarters average of 36.4
The company's debt has surged by 67% YoY and by 66% QoQ
The quick ratio has contracted by 24% YoY and by 3.3% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.transmedics.com
Peers: OBIO OM

Key stats

What are the main financial stats of TMDX

TMDX stock price

How has the TransMedics Group stock price performed over time
Intraday
2.4%
1 week
5.2%
1 month
-26.49%
1 year
-45.03%
YTD
-41.34%
QTD
-28.22%

Financial performance

How have TransMedics Group's revenue and profit performed over time
Revenue
$635.89M
Gross profit
$375.74M
Operating income
$94.44M
Net income
$171.92M
Gross margin
59.1%
Net margin
27%
The company's net margin has surged by 170% YoY but it fell by 14% QoQ
TMDX's operating income has soared by 80% YoY but it is down by 13% QoQ
The operating margin has increased by 38% year-on-year but it has declined by 17% since the previous quarter
The revenue has grown by 30% YoY and by 5% from the previous quarter

Price vs fundamentals

How does TMDX's price correlate with its fundamentals

Growth

What is TransMedics Group's growth rate over time

Valuation

What is TransMedics Group stock price valuation
TMDX P/E details
P/E
14.13
P/B
4.96
P/S
3.86
EV/EBIT
26.68
EV/EBITDA
20.07
EV/Sales
4.48
TMDX's P/E is 62% below its last 4 quarters average of 36.4
TransMedics Group's EPS has decreased by 10% QoQ
TMDX's equity has surged by 86% year-on-year and by 4.4% since the previous quarter
The stock's P/B is 64% less than its 5-year quarterly average of 13.3 and 53% less than its last 4 quarters average of 10.2
The P/S is 73% lower than the 5-year quarterly average of 14.2 and 45% lower than the last 4 quarters average of 6.9
The revenue has grown by 30% YoY and by 5% from the previous quarter

Efficiency

How efficient is TransMedics Group business performance
The ROA has soared by 159% year-on-year but it is down by 22% since the previous quarter
TransMedics Group's return on equity has surged by 91% YoY but it has decreased by 22% QoQ
The ROIC has grown by 32% YoY but it has contracted by 26% from the previous quarter
TransMedics Group's return on sales has increased by 27% YoY but it has decreased by 16% QoQ

Dividends

What is TMDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TMDX.

Financial health

How did TransMedics Group financials performed over time
The total assets is 53% more than the total liabilities
The total assets has soared by 71% YoY and by 34% from the previous quarter
The total liabilities has surged by 65% year-on-year and by 58% since the previous quarter
The company's debt is 75% higher than its equity
TMDX's equity has surged by 86% year-on-year and by 4.4% since the previous quarter
The company's debt has surged by 67% YoY and by 66% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.